Persistent lipid abnormalities in statin-treated patients with diabetes mellitus in Europe and Canada: results of the Dyslipidaemia International Study.
about
Origin and therapy for hypertriglyceridaemia in type 2 diabetesFactors influencing dyslipidemia in statin-treated patients in Lebanon and Jordan: results of the Dyslipidemia International StudyCurrent practice in identifying and treating cardiovascular risk, with a focus on residual risk associated with atherogenic dyslipidaemia.Design and rationale of the ODYSSEY DM-DYSLIPIDEMIA trial: lipid-lowering efficacy and safety of alirocumab in individuals with type 2 diabetes and mixed dyslipidaemia at high cardiovascular risk.Does combination therapy with statins and fibrates prevent cardiovascular disease in diabetic patients with atherogenic mixed dyslipidemia?Impact of lipid-lowering therapy on the prevalence of dyslipidaemia in patients at high-risk of cardiovascular events in UK primary care - a retrospective database study.Critical illness polyneuropathy (CIP) in neurological early rehabilitation: clinical and neurophysiological features.How can we further improve the LDL-cholesterol target level achievement rate based on the Hungarian MULTI GAP 2011 study results and considering the new European dyslipidemia guidelines?Persistent hypertriglyceridemia in statin-treated patients with type 2 diabetes mellitus.Atherogenic dyslipidemia and risk of silent coronary artery disease in asymptomatic patients with type 2 diabetes: a cross-sectional study.Prevalence of dyslipidaemia in statin-treated patients in South Africa: results of the DYSlipidaemia International Study (DYSIS)Ezetimibe/simvastatin: a guide to its clinical use in hypercholesterolemia.Current Phase II proprotein convertase subtilisin/kexin 9 inhibitor therapies for dyslipidemia.Demystifying the management of hypertriglyceridaemia.Saroglitazar for the treatment of dyslipidemia in diabetic patients.Ameliorative effects of Nigella sativa on dyslipidemia.Safety considerations with fenofibrate/simvastatin combination.Pharmacological management of diabetic dyslipidemia.Dyslipidaemia and its treatment in patients with type 2 diabetes - a joint analysis of the German DIVE and DPV registries.Risk factors for cardiovascular disease in patients with COPD: mild-to-moderate COPD versus severe-to-very severe COPD.Triglyceride and HDL-C Dyslipidemia and Risks of Coronary Heart Disease and Ischemic Stroke by Glycemic Dysregulation Status: The Strong Heart Study.Assessment of cardiometabolic risk and prevalence of meeting treatment guidelines among patients with type 2 diabetes stratified according to their use of insulin and/or other diabetic medications: results from INSPIRE ME IAA.Efficacy and safety of alirocumab in insulin-treated individuals with type 1 or type 2 diabetes and high cardiovascular risk: The ODYSSEY DM-INSULIN randomized trial.Persistent lipid abnormalities in patients with hypertension and dyslipidemia treated with statins: results of the Portuguese hypertensive subpopulation of the Dyslipidemia International Study (DYSIS).Efficacy and Safety of Alirocumab in Individuals with Diabetes Mellitus: Pooled Analyses from Five Placebo-Controlled Phase 3 Studies.
P2860
Q26824004-2713AE9E-7426-43FC-A9C7-1C687A6B51ADQ33630826-A25C07A2-AA0F-43F8-8680-A40FF521698BQ33646780-C3BD08CC-18CB-42C8-ADB2-67DF8479AFD4Q33730396-96A44FFD-13D6-4AF3-BC7E-EA5100478B8BQ33776187-98EB16B4-B492-4508-BFB2-ABB60FA87D5DQ34512586-733826F5-24B3-4C10-9636-99FD480284E0Q36225649-AA275A33-5EAD-4F91-A631-B036D9F3CE4DQ36286263-0F46D5CF-8FE9-4689-8972-10A7BBDE223FQ36538599-5F550DBC-C9C6-4A77-8EED-E19CF869F29BQ37119482-F86FC2F4-1648-4B3D-A825-249C6D138417Q37289807-5E6AAC36-9B4A-468A-A328-203E7AEFE2C3Q37972314-C7359B7B-DC5C-4E87-AFDA-4E65F9C8F9E2Q38124404-C399E667-4296-494F-9768-7C18D0EB7C80Q38141575-E5567F4B-6C2F-4652-8877-A9C793E42B26Q38352759-B55AECA3-04B6-44C3-84AB-602F68BD1C45Q38541736-6A014244-181D-4243-9569-BA1652E46C5DQ38541832-439AA734-57DC-4C05-856B-203D25D105D2Q39015072-A8316087-0BD1-483C-AE72-CA3CF9D9A918Q39424127-1995FA67-7941-4401-A774-7A83B118F500Q39627275-868849B9-8008-4D96-91CD-299E3E1BA7D2Q40364483-D54E1D98-DF35-47A9-BBF3-A080190675D5Q43527297-059D1AAB-3742-40FC-A8C0-D3EC8DFD4E14Q44847105-68D81FA3-AD3E-4DC2-93BA-8ADA34E9FE15Q53090578-24B7E27B-BB40-4515-AD05-F63D07829947Q55259756-F93C9FA9-E402-4195-ACF7-E314ADC31D70
P2860
Persistent lipid abnormalities in statin-treated patients with diabetes mellitus in Europe and Canada: results of the Dyslipidaemia International Study.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
2011年论文
@zh
2011年论文
@zh-cn
name
Persistent lipid abnormalities ...... ipidaemia International Study.
@en
type
label
Persistent lipid abnormalities ...... ipidaemia International Study.
@en
prefLabel
Persistent lipid abnormalities ...... ipidaemia International Study.
@en
P2093
P2860
P1433
P1476
Persistent lipid abnormalities ...... ipidaemia International Study.
@en
P2093
DYSIS investigators
L A Leiter
P M da Silva
P2860
P304
P356
10.1111/J.1464-5491.2011.03360.X
P577
2011-11-01T00:00:00Z